Rafarma Pharmaceuticals has undertaken a re-organization of the company

Rafarma Pharmaceuticals, Inc. is pleased to announce that the re-organization of the Company was formalized by FINRA effective on Tuesday, December 4, 2012. With the combination of the asset base of the former Johnston Acquisition Corp.--the financial survivor--and the marketing expertise contributed by Rafarma Pharmaceutical, Inc.--the legal survivor (previously Airprotek International, Inc, Rafarma Pharmaceuticals is well-positioned to become a leading player in the generic and speciality pharmaceutical industry. The Company’s current stock symbol, APKND, will change to a symbol better representing the Company on January 3, 2013. The symbol will be announced by FINRA on January 2, 2013.


The Company welcomes Mr. David L. Anderson as the Company’s newest Board Member and initial C.E.O. of Rafarma Pharmaceuticals, Inc. He is well experienced in Sales and Marketing, speaks fluent Spanish, and has extensive Latin American contacts which mesh ideally with the Company’s expansion goals in Central and South America.


The Company’s “Information and Disclosure Statement” using the “Alternate Reporting Standard” was accepted by OTC Markets on December 5, 2012 and published on the OTC Markets website – www.otcmarkets.com – on December 6, 2012.


Although a merger was involved in the re-organization, no dilution was experienced by the minority shareholders of Johnston Acquisition Corp due to the resignation to the Company’s treasury of securities held by a major shareholder.


The Company would like to express its thanks and appreciation to the large number of shareholders and interested parties who remained loyal to the Company during the re-organization. The Company website – www.rafarma.com – will be frequently updated during the remainder of December. It is anticipated the Company’s Public Relations Department will be fully operational by January 7, 2013.


Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate,", "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.

SOURCE: Rafarma Pharmaceuticals, Inc.